DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study
Status:
Withdrawn
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The study will evaluate if DP-VPA, a derivative of valproate (a drug that is commonly used
for the prevention of migraine attacks), can reduce the rate of migraine attacks.
Migraine patients will take DP-VPA or placebo (an inactive look-alike drug) every morning and
will have to report any migraine attacks they have during the study's 18-week follow up.